Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
| Buy | Overweight | Hold | Underweight | Sell |
|---|---|---|---|---|
| 12 | 3 | 0 | 0 | 0 |
Analyst Firms Making Recommendations1
- Cantor Fitzgerald
- Morgan Stanley
- B. Riley Securities
- JMP Securities
- Needham
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Bicycle Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 11/08/2023 | BCYC | Buy Now | Bicycle Therapeutics | $14.10 | 360.99% | Cantor Fitzgerald | Li Watsek | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 11/03/2023 | BCYC | Buy Now | Bicycle Therapeutics | $14.10 | 183.69% | Morgan Stanley | Jeffrey Hung | $42 → $40 | Maintains | Equal-Weight | Get Alert |
| 09/12/2023 | BCYC | Buy Now | Bicycle Therapeutics | $14.10 | 134.04% | B. Riley Securities | Kalpit Patel | → $33 | Upgrade | Neutral → Buy | Get Alert |
| 09/12/2023 | BCYC | Buy Now | Bicycle Therapeutics | $14.10 | 360.99% | Cantor Fitzgerald | Li Watsek | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 09/12/2023 | BCYC | Buy Now | Bicycle Therapeutics | $14.10 | 212.06% | JMP Securities | Reni Benjamin | → $44 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 09/12/2023 | BCYC | Buy Now | Bicycle Therapeutics | $14.10 | 226.24% | Needham | Ami Fadia | → $46 | Reiterates | Buy → Buy | Get Alert |
| 09/11/2023 | BCYC | Buy Now | Bicycle Therapeutics | $14.10 | 134.04% | B. Riley Securities | Kalpit Patel | $33 → $33 | Upgrade | Neutral → Buy | Get Alert |
| 09/07/2023 | BCYC | Buy Now | Bicycle Therapeutics | $14.10 | 360.99% | Cantor Fitzgerald | Li Watsek | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/04/2023 | BCYC | Buy Now | Bicycle Therapeutics | $14.10 | 197.87% | Morgan Stanley | Jeffrey Hung | $42 → $42 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 08/04/2023 | BCYC | Buy Now | Bicycle Therapeutics | $14.10 | 212.06% | JMP Securities | Reni Benjamin | $46 → $44 | Maintains | Outperform | Get Alert |
| 08/04/2023 | BCYC | Buy Now | Bicycle Therapeutics | $14.10 | 304.26% | HC Wainwright & Co. | Swayampakula Ramakanth | → $57 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | BCYC | Buy Now | Bicycle Therapeutics | $14.10 | 226.24% | Needham | Ami Fadia | $48 → $46 | Maintains | Buy | Get Alert |
| 08/03/2023 | BCYC | Buy Now | Bicycle Therapeutics | $14.10 | 254.61% | EF Hutton | Tony Butler | → $50 | Reiterates | → Buy | Get Alert |
| 05/11/2023 | BCYC | Buy Now | Bicycle Therapeutics | $14.10 | 226.24% | JMP Securities | Reni Benjamin | $46 → $46 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/08/2023 | BCYC | Buy Now | Bicycle Therapeutics | $14.10 | 290.07% | Oppenheimer | Jay Olson | → $55 | Reiterates | → Outperform | Get Alert |
| 05/05/2023 | BCYC | Buy Now | Bicycle Therapeutics | $14.10 | 226.24% | JMP Securities | Reni Benjamin | → $46 | Reiterates | → Market Outperform | Get Alert |
| 05/05/2023 | BCYC | Buy Now | Bicycle Therapeutics | $14.10 | 304.26% | HC Wainwright & Co. | Swayampakula Ramakanth | → $57 | Reiterates | → Buy | Get Alert |
| 05/05/2023 | BCYC | Buy Now | Bicycle Therapeutics | $14.10 | 353.9% | Needham | Ami Fadia | $67 → $64 | Maintains | Buy | Get Alert |
| 04/19/2023 | BCYC | Buy Now | Bicycle Therapeutics | $14.10 | 290.07% | EF Hutton | Tony Butler | → $55 | Reiterates | → Buy | Get Alert |
What is the target price for Bicycle Therapeutics (BCYC)?
The latest price target for Bicycle Therapeutics (NASDAQ: BCYC) was reported by Cantor Fitzgerald on November 8, 2023. The analyst firm set a price target for $65.00 expecting BCYC to rise to within 12 months (a possible 360.99% upside). 28 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bicycle Therapeutics (BCYC)?
The latest analyst rating for Bicycle Therapeutics (NASDAQ: BCYC) was provided by Cantor Fitzgerald, and Bicycle Therapeutics reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Bicycle Therapeutics (BCYC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bicycle Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bicycle Therapeutics was filed on November 8, 2023 so you should expect the next rating to be made available sometime around November 8, 2024.
Is the Analyst Rating Bicycle Therapeutics (BCYC) correct?
While ratings are subjective and will change, the latest Bicycle Therapeutics (BCYC) rating was a reiterated with a price target of $0.00 to $65.00. The current price Bicycle Therapeutics (BCYC) is trading at is $14.10, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.